Summary
Vertex Pharmaceuticals (VRTX) announced a significant licensing agreement with Janssen Pharmaceuticals, Inc. on June 12, 2014, for the development and commercialization of its novel influenza medicine, VX-787, and a backup compound, VX-353. This deal represents a strategic move for Vertex, allowing it to leverage Janssen's expertise and global reach while mitigating development costs and risks associated with bringing a new drug to market. The agreement involves an upfront payment to Vertex and potential future milestone payments and royalties, providing immediate financial benefit and a path to long-term revenue generation.
Key Highlights
- 1Vertex entered into a material definitive agreement with Janssen Pharmaceuticals, Inc. on June 13, 2014.
- 2Janssen has been granted an exclusive worldwide license to develop and commercialize VX-787, an influenza medicine discovered by Vertex.
- 3Vertex will receive an upfront payment of $30.0 million from Janssen.
- 4The agreement also includes potential future development and commercial milestone payments, as well as royalties on any future product sales.
- 5Janssen will assume responsibility for all costs related to the development and commercialization of VX-787 and VX-353.
- 6The transaction is subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Frequently Asked Questions
The agreement allows Vertex to license its novel influenza medicine, VX-787, and a backup compound, VX-353, to Janssen for worldwide development and commercialization. This allows Vertex to benefit from Janssen's expertise and resources while reducing its own financial and operational burden for these specific assets.
Vertex will receive an upfront payment of $30.0 million from Janssen. Additionally, the agreement provides for potential future milestone payments and royalties on any successful commercial sales of the licensed products.
Janssen Pharmaceuticals, Inc. will be responsible for all costs related to the development and commercialization of both VX-787 and the backup compound VX-353.
Yes, the licenses granted and the upfront payment are subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, which is a standard regulatory review process for such transactions.